Singuliar (montelukast) chewable tablets 4 mg. №28


Manufacturer: USA



As adjunctive treatment for bronchial asthma in patients aged 2 to 5 years with mild to moderate persistent asthma, insufficiently controlled by inhaled corticosteroids, and insufficient clinical control of asthma by short-acting β-adrenergic receptor agonists. As an alternative treatment instead of low doses of inhaled corticosteroids for patients 2 to 5 years of age with persistent mild asthma who have not observed any recent major seizures of bronchial asthma requiring oral corticosteroids, or who cannot use corticosteroids. Prevention of asthma, a dominant component of which is exercise-induced bronchospasm in patients 2 years of age and older. Relieving symptoms of seasonal and year-round allergic rhinitis.